Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zalcitabine

FDA-approved product (tablet, oral), marketed as Hivid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Zalcitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF03

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Zalcitabine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zalcitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zalcitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

    NCT06967753 · start 2025-07-31

    Registered record
    Registry ID
    NCT06967753
    Conditions
    HIV; HIV-1
    Interventions
    Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-31
    Completion
    2027-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV-1
    InterventionDolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
    PhasePhase 4
    Registry statusRecruiting

  • Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment

    NCT07062614 · start 2025-07-03

    Registered record
    Registry ID
    NCT07062614
    Conditions
    HIV (Human Immunodeficiency Virus)
    Interventions
    Hair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-03
    Completion
    2027-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV (Human Immunodeficiency Virus)
    InterventionHair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment
    PhaseNot recorded
    Registry statusRecruiting

  • UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study

    NCT06158126 · start 2024-04-17

    Registered record
    Registry ID
    NCT06158126
    Conditions
    Pre-exposure Prophylaxis; HIV Prevention; Pregnancy Related
    Interventions
    Initiating daily oral PrEP during pregnancy; Already using daily oral PrEP at the time of pregnancy diagnosis; Initiating injectable PrEP during pregnancy; Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-04-17
    Completion
    2027-12
    Enrolment
    621

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-exposure Prophylaxis; HIV Prevention; Pregnancy Related
    InterventionInitiating daily oral PrEP during pregnancy; Already using daily oral PrEP at the time of pregnancy diagnosis; Initiating injectable PrEP during pregnancy; Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
    PhasePhase 4
    Registry statusRecruiting

  • Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

    NCT04696575 · start 2021-07-02

    Registered record
    Registry ID
    NCT04696575
    Conditions
    Extensive Stage Lung Small Cell Carcinoma
    Interventions
    Atezolizumab; Carboplatin; Etoposide; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-07-02
    Completion
    2027-07-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Lung Small Cell Carcinoma
    InterventionAtezolizumab; Carboplatin; Etoposide; Lamivudine
    PhasePhase 2
    Registry statusRecruiting

  • Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

    NCT04903847 · start 2021-02-02

    Registered record
    Registry ID
    NCT04903847
    Conditions
    Hiv; HIV Infections; HIV Lipodystrophy; Osteoporosis; Renal Insufficiency; Weight Gain; Obesity
    Interventions
    Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-02-02
    Completion
    2023-02-02
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv; HIV Infections; HIV Lipodystrophy; Osteoporosis +3 more
    InterventionDolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
    PhasePhase 4
    Registry statusUnknown

  • REal-Life Cohort With DOlutegravir + LAmivudina

    NCT04638686 · start 2020-06-15

    Registered record
    Registry ID
    NCT04638686
    Conditions
    HIV-1-infection
    Interventions
    Dolutegravir 50 MG; Lamivudine 300 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-15
    Completion
    2022-03-31
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDolutegravir 50 MG; Lamivudine 300 MG
    PhaseNot recorded
    Registry statusCompleted

  • Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV

    NCT03869944 · start 2019-12-04

    Registered record
    Registry ID
    NCT03869944
    Conditions
    HIV-1
    Interventions
    Lamivudine Oral Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-12-04
    Completion
    2022-03
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionLamivudine Oral Solution
    PhasePhase 2
    Registry statusUnknown

  • 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

    NCT04019873 · start 2019-11-18

    Registered record
    Registry ID
    NCT04019873
    Conditions
    HIV Infections
    Interventions
    Dolutegravir (DTG); Lamivudine (3TC); Rilpivirine (RPV)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-11-18
    Completion
    2023-12-05
    Enrolment
    774

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDolutegravir (DTG); Lamivudine (3TC); Rilpivirine (RPV)
    PhaseNot recorded
    Registry statusCompleted

  • Optimization of Antiretroviral Therapy

    NCT02935075 · start 2018-03-05

    Registered record
    Registry ID
    NCT02935075
    Conditions
    HIV Infections
    Interventions
    Tenofovir disoproxil fumarate; Lamivudine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-05
    Completion
    2019-08-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir disoproxil fumarate; Lamivudine; Efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Nevirapine + 3TC Based Maintenance Therapy for HIV Infection

    NCT03223402 · start 2016-12-23

    Registered record
    Registry ID
    NCT03223402
    Conditions
    HIV Infections
    Interventions
    Nevirapine plus lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-12-23
    Completion
    2018-05-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine plus lamivudine
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

    NCT02777229 · start 2016-07

    Registered record
    Registry ID
    NCT02777229
    Conditions
    HIV-1 Infection
    Interventions
    Dolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07
    Completion
    2021-07
    Enrolment
    616

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    PhasePhase 3
    Registry statusCompleted

  • Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

    NCT02738931 · start 2016-05

    Registered record
    Registry ID
    NCT02738931
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    Dolutegravir 50 mg tablet; Lamivudine 300 mg tablet; Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA); Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05
    Completion
    2016-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionDolutegravir 50 mg tablet; Lamivudine 300 mg tablet; Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA); Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

    NCT02596334 · start 2015-12-23

    Registered record
    Registry ID
    NCT02596334
    Conditions
    HIV
    Interventions
    dolutegravir 50mg +abacavir 600mg +lamivudine 300mg; dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-12-23
    Completion
    2018-06-23
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiondolutegravir 50mg +abacavir 600mg +lamivudine 300mg; dolutegravir
    PhasePhase 3
    Registry statusTerminated

  • The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

    NCT02581202 · start 2015-12-21

    Registered record
    Registry ID
    NCT02581202
    Conditions
    HIV-1 Infection
    Interventions
    lopinavir/ritonavir; lamivudine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-12-21
    Completion
    2017-05-27
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionlopinavir/ritonavir; lamivudine
    PhaseNot recorded
    Registry statusCompleted

  • Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

    NCT02582684 · start 2015-12-08

    Registered record
    Registry ID
    NCT02582684
    Conditions
    HIV-1 Infection
    Interventions
    Dolutegravir; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12-08
    Completion
    2017-09-26
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDolutegravir; Lamivudine
    PhasePhase 2
    Registry statusCompleted